FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025 at 4:30 p.m. PT. A live webcast of the presentation will be available on the investor relations page o ...

Terns Pharmaceuticals Inc.’s stock was soaring 14% Wednesday, as analysts cheered positive data released a day earlier on a treatment for chronic myeloid leukemia.The data from an early-stage trial of TERN-701 were very encouraging, according to Mizuho analysts Graig Suvannavejh and Avantika Joshi. ...

FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company’s Board of Directors, effective immediately. In conjunction with Ms. Turner’s appointment ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39926 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------- ...

Exhibit 99.1 Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early December 2024 Plans to initiate Phase 2 clinical trial for TERN-601 in obesity in early 2Q25 with initial 12-week data expected in 2H25 Cash, cash equivalents and marketable securities of $372.8 million, including $ ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Terns Pharmaceuticals just proved that it's competitive in the weight loss field. Shares of biotechnology companies like Viking Therapeutics (VKTX 6.24%) have exploded upward by over 300% in the last 12 months, thanks to its phenomenal clinical data from its late-stage weight loss drug program. The biotech industry is frequently rife with exciting opportunities for the more risk-tolerant investors, and it should come as no surprise that investors who missed the Viking rally may be looking for a similar oppo ...

Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling. What is the hot, new, exciting, and fast-growing therapeutic area many drugmakers are trying to break into? If you guessed weight loss, you are right on the money. Therapies in this field, such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy, are generating mouthwatering sales, so it's no wonder other companies are looking for a piece of the pie. It's not just prominent players in the industry, either: Many ...

This biotech's data suggests that it could have an advantage in its target market. If you have $1,000 that you don't really need for some immediate expense, or aren't saving it for a big ticket purchase, putting that amount to work by investing it may be a solid option. With competition in the weight loss drugs market picking up sharply and showing only signs of further acceleration, now's a smart time for investors to position themselves in the most credible contenders for tomorrow's winners. But here's th ...

FOSTER CITY, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smallmolecule product candidates to address serious diseases, including oncology and obesity, today announced the closing of its previously announced underwritten public offering of 14,064,048 shares of its common stock, including 2,145,000 shares sold pursuant to the underwriters' exercise in full of their option ...